Skip to main content
Erschienen in: Drug Safety 2/2011

01.02.2011 | Original Research Article

Effects of Benzodiazepines, Antidepressants and Opioids on Driving

A Systematic Review and Meta-Analysis of Epidemiological and Experimental Evidence

verfasst von: Dr Tharaka Dassanayake, Patricia Michie, Gregory Carter, Alison Jones

Erschienen in: Drug Safety | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background: Many individuals in the community are prescribed psychoactive drugs with sedative effects. These drugs may affect their daily functions, of which automobile driving is a major component.
Objective: To examine the association of three classes of commonly used psychoactive drugs (viz. benzodiazepines and newer non-benzodiazepine hypnotics, antidepressants and opioids) with (i) the risk of traffic accidents (as indexed by epidemiological indicators of risk); and (ii) driving performance (as indexed by experimental measures of driving performance).
Methods: A literature search for material published in the English language between January 1966 and January 2010 in PubMed and EMBASE databases was combined with a search for other relevant material referenced in the retrieved articles. Retrieved articles were systematically reviewed, carrying out meta-analyses where possible. Twenty-one epidemiological studies (13 case-control and 8 cohort studies) fulfilled the inclusion criteria by estimating the accident risk associated with drug exposure (ascertained by blood/urine analysis or prescription records). Sixty-nine experimental studies fulfilled the inclusion criteria by testing actual or simulated driving performance after administering a single dose or multiple doses.
Results: Two meta-analyses showed that benzodiazepines are associated with a 60% (for case-control studies: pooled odds ratio [OR] 1.59; 95% CI 1.10, 2.31) to 80% (for cohort studies: pooled incidence rate ratio 1.81; 95% CI 1.35, 2.43) increase in the risk of traffic accidents and a 40% (pooled OR 1.41; 95% CI 1.03, 1.94) increase in ‘accident responsibility’. Co-ingestion of benzodiazepines and alcohol was associated with a 7.7-fold increase in the accident risk (pooled OR 7.69; 95% CI 4.33, 13.65). Subgroup analysis of case-control studies showed a lower benzodiazepine-associated accident risk in elderly (>65 years of age) drivers (pooled OR 1.13; 95% CI 0.97,1.31) than in drivers <65 years of age (pooled OR 2.21; 95% CI 1.31, 3.73), a result consistent with age-stratified risk differences reported in cohort studies. Anxiolytics, taken in single or multiple doses during the daytime, impaired driving performance independent of their half-lives. With hypnotics, converging evidence from experimental and epidemiological studies indicates that diazepam, flurazepam, flunitrazepam, nitrazepam and the short half-life non-benzodiazepine hypnotic zopiclone significantly impair driving, at least during the first 2–4 weeks of treatment. The accident risk was higher in the elderly (>65 years of age) who use tricyclic antidepressants (TCAs); however, the evidence for an association of antidepressants with accident risk in younger drivers was equivocal. Sedative but not non-sedative antidepressants were found to cause short-term impairment of several measures of driving performance. Limited epidemiological research reported that opioids may be associated with increased accident risk in the first few weeks of treatment.
Conclusions: Benzodiazepine use was associated with a significant increase in the risk of traffic accidents and responsibility of drivers for accidents. The association was more pronounced in the younger drivers. The accident risk was markedly increased by co-ingestion of alcohol. Driving impairment was generally related to plasma half-lives of hypnotics, but with notable exceptions. Anxiolytics, with daytime dosing, impaired driving independent of their half-lives. TCAs appeared to be associated with increased accident risk, at least in the elderly, and caused short-term impairment in driving performance. Opioid users may be at a higher risk of traffic accidents; however, experimental evidence is limited on their effects on driving.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Amado-Boccara I, Gougoulis N, Poirier Littre MF, et al. Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 1995; 19(3): 479–93PubMedCrossRef Amado-Boccara I, Gougoulis N, Poirier Littre MF, et al. Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 1995; 19(3): 479–93PubMedCrossRef
2.
Zurück zum Zitat Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66 Suppl. 2: 9–13PubMed Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66 Suppl. 2: 9–13PubMed
3.
Zurück zum Zitat Thompson PJ. Antidepressants and memory. Hum Psychopharmacol 1991; 6: 79–90CrossRef Thompson PJ. Antidepressants and memory. Hum Psychopharmacol 1991; 6: 79–90CrossRef
4.
Zurück zum Zitat Longo MC, Hunter CE, Lokan RJ, et al. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part II. The relationship between drug prevalence and drug concentration, and driver culpability. Accid Anal Prev 2000; 32(5): 623–32PubMedCrossRef Longo MC, Hunter CE, Lokan RJ, et al. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part II. The relationship between drug prevalence and drug concentration, and driver culpability. Accid Anal Prev 2000; 32(5): 623–32PubMedCrossRef
5.
Zurück zum Zitat O’Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18 Suppl. 1: 121–9SCrossRef O’Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18 Suppl. 1: 121–9SCrossRef
6.
Zurück zum Zitat Hindmarch I, Hanks GW, Hewett AJ. Clobazam, a 1,5-benzodiazepine, and car-driving ability. Br J Clin Pharmacol 1977; 4(5): 573–8PubMedCrossRef Hindmarch I, Hanks GW, Hewett AJ. Clobazam, a 1,5-benzodiazepine, and car-driving ability. Br J Clin Pharmacol 1977; 4(5): 573–8PubMedCrossRef
7.
Zurück zum Zitat Mercier-Guyon C, Lejay J, Choay P. Comparative study of the effects of captodiamine and lorazepam on car driving ability. Clin Drug Investig 1999; 17(6): 451–9CrossRef Mercier-Guyon C, Lejay J, Choay P. Comparative study of the effects of captodiamine and lorazepam on car driving ability. Clin Drug Investig 1999; 17(6): 451–9CrossRef
8.
Zurück zum Zitat Iwamoto K, Kawamura Y, Takahashi M, et al. Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers. Psychiatry Clin Neurosci 2008; 62(5): 610–6PubMedCrossRef Iwamoto K, Kawamura Y, Takahashi M, et al. Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers. Psychiatry Clin Neurosci 2008; 62(5): 610–6PubMedCrossRef
9.
Zurück zum Zitat Linnoila M, Hakkinen S. Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving. Clin Pharmacol Ther 1974 Apr; 15(4): 368–73PubMed Linnoila M, Hakkinen S. Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving. Clin Pharmacol Ther 1974 Apr; 15(4): 368–73PubMed
10.
Zurück zum Zitat Willumeit HP, Ott H, Neubert W. Simulated car driving as a useful technique for the determination of residual effects and alcohol interaction after short- and long-acting benzodiazepines. Psychopharmacology (Berl) 1984; 1 Suppl.: 182–92 Willumeit HP, Ott H, Neubert W. Simulated car driving as a useful technique for the determination of residual effects and alcohol interaction after short- and long-acting benzodiazepines. Psychopharmacology (Berl) 1984; 1 Suppl.: 182–92
11.
Zurück zum Zitat Michon JA. A critical view of driver behavior models: what do we know, what should we do? In: Evans L, Schwing RC, editors. Human behavior and traffic safety. New York: Plenum Press, 1985: 485–520CrossRef Michon JA. A critical view of driver behavior models: what do we know, what should we do? In: Evans L, Schwing RC, editors. Human behavior and traffic safety. New York: Plenum Press, 1985: 485–520CrossRef
12.
Zurück zum Zitat Michon JA. Explanatory pitfalls and rule-based driver models. Accid Anal Prev 1989; 21(4): 341–53PubMedCrossRef Michon JA. Explanatory pitfalls and rule-based driver models. Accid Anal Prev 1989; 21(4): 341–53PubMedCrossRef
13.
Zurück zum Zitat van der Molen HH, Botticher AMT. A hierarchical risk model for traffic participants. Ergonomics 1988; 31(4): 537–55CrossRef van der Molen HH, Botticher AMT. A hierarchical risk model for traffic participants. Ergonomics 1988; 31(4): 537–55CrossRef
14.
Zurück zum Zitat Verster JC, Volkerts ER, Spence DW, et al. Effects of sleep medications on cognition, psychomotor skills, memory and driving performance in the elderly. Curr Psychiatry Rev 2007; 3(4): 281–92CrossRef Verster JC, Volkerts ER, Spence DW, et al. Effects of sleep medications on cognition, psychomotor skills, memory and driving performance in the elderly. Curr Psychiatry Rev 2007; 3(4): 281–92CrossRef
15.
Zurück zum Zitat Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004; 18(5): 297–328PubMedCrossRef Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004; 18(5): 297–328PubMedCrossRef
16.
Zurück zum Zitat Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003; 64(1): 20–9PubMedCrossRef Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003; 64(1): 20–9PubMedCrossRef
17.
Zurück zum Zitat Bachs LC, Engeland A, Morland JG, et al. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clin Pharmacol Ther 2009; 85(6): 596–9PubMedCrossRef Bachs LC, Engeland A, Morland JG, et al. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clin Pharmacol Ther 2009; 85(6): 596–9PubMedCrossRef
18.
Zurück zum Zitat Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008; 9(8): 818–22PubMedCrossRef Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008; 9(8): 818–22PubMedCrossRef
19.
Zurück zum Zitat Bramness JG, Skurtveit S, Morland J, et al. The risk of traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007; 39(5): 1050–5PubMedCrossRef Bramness JG, Skurtveit S, Morland J, et al. The risk of traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007; 39(5): 1050–5PubMedCrossRef
20.
Zurück zum Zitat Skegg DC, Richards SM, Doll R. Minor tranquillisers and road accidents. BMJ 1979; 1(6168): 917–9PubMedCrossRef Skegg DC, Richards SM, Doll R. Minor tranquillisers and road accidents. BMJ 1979; 1(6168): 917–9PubMedCrossRef
21.
Zurück zum Zitat Honkanen R, Ertama L, Linnoila M. Role of drugs in traffic accidents. BMJ 1980; 281(6251): 1309–12PubMedCrossRef Honkanen R, Ertama L, Linnoila M. Role of drugs in traffic accidents. BMJ 1980; 281(6251): 1309–12PubMedCrossRef
22.
Zurück zum Zitat Jick H, Hunter JR, Dinan BJ, et al. Sedating drugs and automobile accidents leading to hospitalization. Am J Public Health 1981; 71(12): 1399–400PubMedCrossRef Jick H, Hunter JR, Dinan BJ, et al. Sedating drugs and automobile accidents leading to hospitalization. Am J Public Health 1981; 71(12): 1399–400PubMedCrossRef
23.
Zurück zum Zitat Lagier G. Are benzodiazepines a risk factor for road accidents? Drug Alcohol Depend 1993; 33(1): 19–22CrossRef Lagier G. Are benzodiazepines a risk factor for road accidents? Drug Alcohol Depend 1993; 33(1): 19–22CrossRef
24.
Zurück zum Zitat Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5(6): 591–8PubMedCrossRef Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5(6): 591–8PubMedCrossRef
25.
Zurück zum Zitat Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278(1): 27–31PubMedCrossRef Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278(1): 27–31PubMedCrossRef
26.
Zurück zum Zitat Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352(9137): 1331–6PubMedCrossRef Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352(9137): 1331–6PubMedCrossRef
27.
Zurück zum Zitat Longo MC, Lokan RJ, White JM. The relationship between blood benzodiazepine concentration and vehicle crash culpability. J Traffic Med 2001; 29(1–2): 36–43 Longo MC, Lokan RJ, White JM. The relationship between blood benzodiazepine concentration and vehicle crash culpability. J Traffic Med 2001; 29(1–2): 36–43
28.
Zurück zum Zitat McGwin Jr G, Sims RV, Pulley L, et al. Relations among chronic medical conditions, medications, and automobile crashes in the elderly: a population-based case-control study. Am J Epidemiol 2000; 152(5): 424–31PubMedCrossRef McGwin Jr G, Sims RV, Pulley L, et al. Relations among chronic medical conditions, medications, and automobile crashes in the elderly: a population-based case-control study. Am J Epidemiol 2000; 152(5): 424–31PubMedCrossRef
29.
Zurück zum Zitat Mura P, Kintz P, Ludes B, et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci Int 2003; 133(1–2): 79–85PubMedCrossRef Mura P, Kintz P, Ludes B, et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci Int 2003; 133(1–2): 79–85PubMedCrossRef
30.
Zurück zum Zitat Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004; 36(2): 239–48PubMedCrossRef Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004; 36(2): 239–48PubMedCrossRef
31.
Zurück zum Zitat Movig KL, Mathijssen MP, Nagel PH, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 2004; 36(4): 631–6PubMedCrossRef Movig KL, Mathijssen MP, Nagel PH, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 2004; 36(4): 631–6PubMedCrossRef
32.
Zurück zum Zitat Dubois S, Bedard M, Weaver B. The impact of benzodiazepines on safe driving. Traffic Inj Prev 2008; 9(5): 404–13PubMedCrossRef Dubois S, Bedard M, Weaver B. The impact of benzodiazepines on safe driving. Traffic Inj Prev 2008; 9(5): 404–13PubMedCrossRef
33.
Zurück zum Zitat Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992 Oct 1; 136(7): 873–83PubMedCrossRef Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992 Oct 1; 136(7): 873–83PubMedCrossRef
34.
Zurück zum Zitat Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995; 5(3): 239–44PubMedCrossRef Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995; 5(3): 239–44PubMedCrossRef
35.
Zurück zum Zitat Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol 1998; 13 Suppl. 2: S115–23CrossRef Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol 1998; 13 Suppl. 2: S115–23CrossRef
36.
Zurück zum Zitat Engeland A, Skurtveit S, Morland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol 2007; 17(8): 597–602PubMedCrossRef Engeland A, Skurtveit S, Morland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol 2007; 17(8): 597–602PubMedCrossRef
37.
Zurück zum Zitat Bramness JG, Skurtveit S, Neutel CI, et al. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. J Clin Psychiatry 2008; 69(7): 1099–103PubMedCrossRef Bramness JG, Skurtveit S, Neutel CI, et al. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. J Clin Psychiatry 2008; 69(7): 1099–103PubMedCrossRef
38.
Zurück zum Zitat Gibson JE, Hubbard RB, Smith CJP, et al. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 2009; 169(6): 761–8PubMedCrossRef Gibson JE, Hubbard RB, Smith CJP, et al. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 2009; 169(6): 761–8PubMedCrossRef
39.
Zurück zum Zitat Drummer OH. The role of drugs in road safety. Aust Prescr 2008; 31(2): 33–5 Drummer OH. The role of drugs in road safety. Aust Prescr 2008; 31(2): 33–5
40.
Zurück zum Zitat Rapoport MJ, Lanctot KL, Streiner DL, et al. Benzodiazepine use and driving: a meta-analysis. J Clin Psychiatry 2009; 70(5): 663–73PubMedCrossRef Rapoport MJ, Lanctot KL, Streiner DL, et al. Benzodiazepine use and driving: a meta-analysis. J Clin Psychiatry 2009; 70(5): 663–73PubMedCrossRef
41.
Zurück zum Zitat Brunnauer A, Laux G, David I, et al. The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. J Clin Psychiatry 2008; 69(12): 1880–6PubMedCrossRef Brunnauer A, Laux G, David I, et al. The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. J Clin Psychiatry 2008; 69(12): 1880–6PubMedCrossRef
42.
Zurück zum Zitat de Gier JJ, Hart BJ, Nelemans FA, et al. Psychomotor performance and real driving performance of outpatients receiving diazepam. Psychopharmacology (Berl) 1981; 73(4): 340–4CrossRef de Gier JJ, Hart BJ, Nelemans FA, et al. Psychomotor performance and real driving performance of outpatients receiving diazepam. Psychopharmacology (Berl) 1981; 73(4): 340–4CrossRef
43.
Zurück zum Zitat Menefee LA, Frank ED, Crerand C, et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med 2004; 5(1): 42–9PubMedCrossRef Menefee LA, Frank ED, Crerand C, et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med 2004; 5(1): 42–9PubMedCrossRef
44.
Zurück zum Zitat Shen J, Moller HJ, Wang X, et al. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry 2009; 70(3): 370–7PubMedCrossRef Shen J, Moller HJ, Wang X, et al. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry 2009; 70(3): 370–7PubMedCrossRef
45.
Zurück zum Zitat Friedel B, Sjoo S, Reker K, et al. Testing drivers taking diazepam in the Daimler-Benz driving simulator. J Traffic Med 1991; 19(1): 15–27 Friedel B, Sjoo S, Reker K, et al. Testing drivers taking diazepam in the Daimler-Benz driving simulator. J Traffic Med 1991; 19(1): 15–27
46.
Zurück zum Zitat O’Hanlon JF, Volkerts ER. Hypnotics and actual driving performance. Acta Psychiatr Scand 1986; 74 Suppl. 332: 95–104CrossRef O’Hanlon JF, Volkerts ER. Hypnotics and actual driving performance. Acta Psychiatr Scand 1986; 74 Suppl. 332: 95–104CrossRef
47.
Zurück zum Zitat Schmidt U, Brendemuhl D, Ruther E. Aspects of driving after hypnotic therapy with particular reference to temazepam. Acta Psychiatr Scand 1986; 74 Suppl. 332: 112–8CrossRef Schmidt U, Brendemuhl D, Ruther E. Aspects of driving after hypnotic therapy with particular reference to temazepam. Acta Psychiatr Scand 1986; 74 Suppl. 332: 112–8CrossRef
48.
Zurück zum Zitat Brookhuis KA, Volkerts ER, O’Hanlon JF. Repeated dose effects of lormetazepam and flurazepam upon driving performance. Eur J Clin Pharmacol 1990; 39(1): 83–7PubMedCrossRef Brookhuis KA, Volkerts ER, O’Hanlon JF. Repeated dose effects of lormetazepam and flurazepam upon driving performance. Eur J Clin Pharmacol 1990; 39(1): 83–7PubMedCrossRef
49.
Zurück zum Zitat Vermeeren A, O’Hanlon JF, Declerck AC, et al. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995; 21(1): 47–64 Vermeeren A, O’Hanlon JF, Declerck AC, et al. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995; 21(1): 47–64
50.
Zurück zum Zitat Partinen M, Hirvonen K, Hublin C, et al. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-oraganic insomnia. Sleep Med 2003; 4(6): 553–61PubMedCrossRef Partinen M, Hirvonen K, Hublin C, et al. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-oraganic insomnia. Sleep Med 2003; 4(6): 553–61PubMedCrossRef
51.
Zurück zum Zitat Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005; 181(4): 790–8CrossRef Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005; 181(4): 790–8CrossRef
52.
Zurück zum Zitat Moore NC. Medazepam and the driving ability of anxious patients. Psychopharmacology (Berl) 1977; 52(1): 103–6CrossRef Moore NC. Medazepam and the driving ability of anxious patients. Psychopharmacology (Berl) 1977; 52(1): 103–6CrossRef
53.
Zurück zum Zitat van Laar MW, Volkerts ER, van Willigenburg AP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12(2): 86–95PubMed van Laar MW, Volkerts ER, van Willigenburg AP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12(2): 86–95PubMed
54.
Zurück zum Zitat O’Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics’ effects on the actual driving performance of patients and healthy volunteers in a standardized test: an integration of three studies. Neuropsychobiology 1995; 31(2): 81–8PubMedCrossRef O’Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics’ effects on the actual driving performance of patients and healthy volunteers in a standardized test: an integration of three studies. Neuropsychobiology 1995; 31(2): 81–8PubMedCrossRef
55.
Zurück zum Zitat Veldhuijzen DS, van Wijck AJ, Verster JC, et al. Acute and subchronic effects of amitriptyline 25 mg on actual driving in chronic neuropathic pain patients. J Psychopharmacol 2006; 20(6): 782–8PubMedCrossRef Veldhuijzen DS, van Wijck AJ, Verster JC, et al. Acute and subchronic effects of amitriptyline 25 mg on actual driving in chronic neuropathic pain patients. J Psychopharmacol 2006; 20(6): 782–8PubMedCrossRef
56.
Zurück zum Zitat Vanakoski J, Mattila MJ, Seppala T. Driving under light and dark conditions: effects of alcohol and diazepam in young and older subjects. Eur J Clin Pharmacol 2000; 56(6–7): 453–8PubMedCrossRef Vanakoski J, Mattila MJ, Seppala T. Driving under light and dark conditions: effects of alcohol and diazepam in young and older subjects. Eur J Clin Pharmacol 2000; 56(6–7): 453–8PubMedCrossRef
57.
Zurück zum Zitat Van Laar MW, Van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995; 15(1): 30–40PubMedCrossRef Van Laar MW, Van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995; 15(1): 30–40PubMedCrossRef
58.
Zurück zum Zitat Leufkens TRM, Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 2009; 29(5): 432–8PubMedCrossRef Leufkens TRM, Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 2009; 29(5): 432–8PubMedCrossRef
59.
Zurück zum Zitat Meskali M, Berthelon C, Marie S, et al. Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study. Psychopharmacology (Berl) 2009; 207(3): 461–7CrossRef Meskali M, Berthelon C, Marie S, et al. Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study. Psychopharmacology (Berl) 2009; 207(3): 461–7CrossRef
60.
Zurück zum Zitat Hindmarch I, Gudgeon AC. The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. Br J Clin Pharmacol 1980; 10(2): 145–50PubMedCrossRef Hindmarch I, Gudgeon AC. The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. Br J Clin Pharmacol 1980; 10(2): 145–50PubMedCrossRef
61.
Zurück zum Zitat Laurell H, Tornros J. The carry-over effects of triazolam compared with nitrazepam and placebo in acute emergency driving situations and in monotonous simulated driving. Acta Pharmacol Toxicol (Copenh) 1986; 58(3): 182–6CrossRef Laurell H, Tornros J. The carry-over effects of triazolam compared with nitrazepam and placebo in acute emergency driving situations and in monotonous simulated driving. Acta Pharmacol Toxicol (Copenh) 1986; 58(3): 182–6CrossRef
62.
Zurück zum Zitat Clayton AB, Harvey PG, Betts TA. The effects of two anti-depressants, imipramine and viloxazine, upon driving performance. Psychopharmacology (Berl) 1977; 55(1): 9–12CrossRef Clayton AB, Harvey PG, Betts TA. The effects of two anti-depressants, imipramine and viloxazine, upon driving performance. Psychopharmacology (Berl) 1977; 55(1): 9–12CrossRef
63.
Zurück zum Zitat Betts TA, Birtle J. Effect of two hypnotic drugs on actual driving performance next morning. BMJ 1982; 285(6345): 852PubMedCrossRef Betts TA, Birtle J. Effect of two hypnotic drugs on actual driving performance next morning. BMJ 1982; 285(6345): 852PubMedCrossRef
64.
Zurück zum Zitat Biehl B. Studies of clobazam and car-driving. Br J Clin Pharmacol 1979; 7 Suppl. 1: 85–90SCrossRef Biehl B. Studies of clobazam and car-driving. Br J Clin Pharmacol 1979; 7 Suppl. 1: 85–90SCrossRef
65.
Zurück zum Zitat Hindmarch I, Subhan Z. The effects of midazolam in conjunction with alcohol on sleep, psychomotor performance and car driving ability. Int J Clin Pharmacol Res 1983; 3(5): 323–9PubMed Hindmarch I, Subhan Z. The effects of midazolam in conjunction with alcohol on sleep, psychomotor performance and car driving ability. Int J Clin Pharmacol Res 1983; 3(5): 323–9PubMed
66.
Zurück zum Zitat Hindmarch I, Subhan Z, Stoker MJ. The effects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr Scand Suppl 1983; 308: 141–6PubMed Hindmarch I, Subhan Z, Stoker MJ. The effects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr Scand Suppl 1983; 308: 141–6PubMed
67.
Zurück zum Zitat Ridout F, Hindmarch I. Effects of tianeptine and mianserin on car driving skills. Psychopharmacology (Berl) 2001; 154(4): 356–61CrossRef Ridout F, Hindmarch I. Effects of tianeptine and mianserin on car driving skills. Psychopharmacology (Berl) 2001; 154(4): 356–61CrossRef
68.
Zurück zum Zitat Boyle J, Trick L, Johnsen S, et al. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 2008; 23(5): 385–97PubMedCrossRef Boyle J, Trick L, Johnsen S, et al. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 2008; 23(5): 385–97PubMedCrossRef
69.
Zurück zum Zitat Willumeit HP, Ott H, Neubert W, et al. Alcohol interaction of lormetazepam, mepindolol sulphate and diazepam measured by performance on the driving simulator. Pharmacopsychiatry 1984; 17(2): 36–43PubMedCrossRef Willumeit HP, Ott H, Neubert W, et al. Alcohol interaction of lormetazepam, mepindolol sulphate and diazepam measured by performance on the driving simulator. Pharmacopsychiatry 1984; 17(2): 36–43PubMedCrossRef
70.
Zurück zum Zitat Volkerts ER, Van Laar MW, Van Willigenburg APP, et al. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol 1992; 7(5): 297–309CrossRef Volkerts ER, Van Laar MW, Van Willigenburg APP, et al. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol 1992; 7(5): 297–309CrossRef
71.
Zurück zum Zitat Kuitunen T. Drug and ethanol effects on the clinical test for drunkenness: single doses of ethanol, hypnotic drugs and antidepressant drugs. Pharmacol Toxicol 1994; 75(2): 91–8PubMedCrossRef Kuitunen T. Drug and ethanol effects on the clinical test for drunkenness: single doses of ethanol, hypnotic drugs and antidepressant drugs. Pharmacol Toxicol 1994; 75(2): 91–8PubMedCrossRef
72.
Zurück zum Zitat Verster JC, Mets MAJ. Psychoactive medication and traffic safety. Int J Environ Res Public Health 6(3): 1041–54 Verster JC, Mets MAJ. Psychoactive medication and traffic safety. Int J Environ Res Public Health 6(3): 1041–54
73.
Zurück zum Zitat Verster JC, Volkerts ER, Olivier B, et al. Zolpidem and traffic safety: the importance of treatment compliance. Curr Drug Saf 2007; 2(3): 220–6PubMedCrossRef Verster JC, Volkerts ER, Olivier B, et al. Zolpidem and traffic safety: the importance of treatment compliance. Curr Drug Saf 2007; 2(3): 220–6PubMedCrossRef
74.
Zurück zum Zitat O’Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982; 217(4554): 79–81PubMedCrossRef O’Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982; 217(4554): 79–81PubMedCrossRef
75.
Zurück zum Zitat Moskowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982; 43(12 II): 45–55PubMed Moskowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982; 43(12 II): 45–55PubMed
76.
Zurück zum Zitat Van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 2001; 154(2): 189–97CrossRef Van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 2001; 154(2): 189–97CrossRef
77.
Zurück zum Zitat Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 2002; 27(2): 260–9PubMedCrossRef Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 2002; 27(2): 260–9PubMedCrossRef
78.
Zurück zum Zitat Leufkens TR, Vermeeren A, Smink BE, et al. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl) 2007; 191(4): 951–9CrossRef Leufkens TR, Vermeeren A, Smink BE, et al. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl) 2007; 191(4): 951–9CrossRef
79.
Zurück zum Zitat Laurell H, Tornros J. Interaction effects of hypnotics and alcohol on driving performance. J Traffic Med 1991; 19(1): 9–13 Laurell H, Tornros J. Interaction effects of hypnotics and alcohol on driving performance. J Traffic Med 1991; 19(1): 9–13
80.
Zurück zum Zitat Bocca ML, Le Doze F, Etard O, et al. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999; 143(4): 373–9CrossRef Bocca ML, Le Doze F, Etard O, et al. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999; 143(4): 373–9CrossRef
81.
Zurück zum Zitat Leufkens TRM, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009; 18(4): 387–96PubMedCrossRef Leufkens TRM, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009; 18(4): 387–96PubMedCrossRef
82.
Zurück zum Zitat Iudice A, Bonanni E, Maestri M, et al. Lormetazepam effects on daytime vigilance, psychomotor performance and simulated driving in young adult healthy volunteers. Int J Clin Pharmacol Ther 2002; 40(7): 304–9PubMed Iudice A, Bonanni E, Maestri M, et al. Lormetazepam effects on daytime vigilance, psychomotor performance and simulated driving in young adult healthy volunteers. Int J Clin Pharmacol Ther 2002; 40(7): 304–9PubMed
83.
Zurück zum Zitat Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998; 13 Suppl. 2: S98–107CrossRef Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998; 13 Suppl. 2: S98–107CrossRef
84.
Zurück zum Zitat Vermeeren A, Riedel WJ, Van Boxtel MPJ, et al. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002; 25(2): 224–31PubMed Vermeeren A, Riedel WJ, Van Boxtel MPJ, et al. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002; 25(2): 224–31PubMed
85.
Zurück zum Zitat Matthews A, Kirkby KC, Martin F. The effects of single-dose lorazepam on memory and behavioural learning. J Psychopharmacol 2002; 16(4): 345–54PubMedCrossRef Matthews A, Kirkby KC, Martin F. The effects of single-dose lorazepam on memory and behavioural learning. J Psychopharmacol 2002; 16(4): 345–54PubMedCrossRef
86.
Zurück zum Zitat Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002; 22(6): 576–83PubMedCrossRef Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002; 22(6): 576–83PubMedCrossRef
87.
Zurück zum Zitat Otmani S, Demazieres A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008; 23(8): 693–705PubMedCrossRef Otmani S, Demazieres A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008; 23(8): 693–705PubMedCrossRef
88.
Zurück zum Zitat Ramaekers JG, Muntjewerff ND, O’Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995; 39(4): 397–404PubMedCrossRef Ramaekers JG, Muntjewerff ND, O’Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995; 39(4): 397–404PubMedCrossRef
89.
Zurück zum Zitat Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005; 66(4): 436–43PubMedCrossRef Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005; 66(4): 436–43PubMedCrossRef
90.
Zurück zum Zitat Veldhuijzen DS, Kenemans JL, Van Wijck AJM, et al. Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings. Psychopharmacology (Berl) 2006; 183(4): 462–70CrossRef Veldhuijzen DS, Kenemans JL, Van Wijck AJM, et al. Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings. Psychopharmacology (Berl) 2006; 183(4): 462–70CrossRef
91.
Zurück zum Zitat Ramaekers JG, Muntjewerff ND, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 1998; 13 Suppl. 2: S87–97CrossRef Ramaekers JG, Muntjewerff ND, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 1998; 13 Suppl. 2: S87–97CrossRef
92.
Zurück zum Zitat Robbe HWJ, O’Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995; 5(1): 35–42PubMedCrossRef Robbe HWJ, O’Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995; 5(1): 35–42PubMedCrossRef
93.
Zurück zum Zitat Iwamoto K, Takahashi M, Nakamura Y, et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum Psychopharmacol 2008; 23(5): 399–407PubMedCrossRef Iwamoto K, Takahashi M, Nakamura Y, et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum Psychopharmacol 2008; 23(5): 399–407PubMedCrossRef
94.
Zurück zum Zitat Hindmarch I, Harrison C, Shillingford CA. An investigation of the effects of lofepramine, nomifensine, amitriptyline and placebo on aspects of memory and psychomotor performance related to car driving. Int Clin Psychopharmacol 1988; 3(2): 157–65PubMedCrossRef Hindmarch I, Harrison C, Shillingford CA. An investigation of the effects of lofepramine, nomifensine, amitriptyline and placebo on aspects of memory and psychomotor performance related to car driving. Int Clin Psychopharmacol 1988; 3(2): 157–65PubMedCrossRef
95.
Zurück zum Zitat Landauer AA, Milner G, Patman J. Alcohol and amitriptyline effects on skills related to driving behavior. Science 1969; 163(3874): 1467–8PubMedCrossRef Landauer AA, Milner G, Patman J. Alcohol and amitriptyline effects on skills related to driving behavior. Science 1969; 163(3874): 1467–8PubMedCrossRef
96.
Zurück zum Zitat Hindmarch I, Subhan Z, Stoker MJ. Comparison of the effects of zimeldine, amitriptyline and placebo on brake reaction time. IRCS Med Sci 1983; 11(6): 532–3 Hindmarch I, Subhan Z, Stoker MJ. Comparison of the effects of zimeldine, amitriptyline and placebo on brake reaction time. IRCS Med Sci 1983; 11(6): 532–3
97.
Zurück zum Zitat Ramaekers JG, Van Veggel LMA, O’Hanlon JF. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Clin Neuropharmacol 1994; 17 Suppl. 1: S9–18PubMedCrossRef Ramaekers JG, Van Veggel LMA, O’Hanlon JF. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Clin Neuropharmacol 1994; 17 Suppl. 1: S9–18PubMedCrossRef
98.
Zurück zum Zitat O’Hanlon JF, Robbe HW, Vermeeren A, et al. Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998; 18(3): 212–21PubMedCrossRef O’Hanlon JF, Robbe HW, Vermeeren A, et al. Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998; 18(3): 212–21PubMedCrossRef
99.
Zurück zum Zitat Verster JC, Veldhuijzen DS, Volkerts ER. Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. Clin J Pain 2006; 22(5): 499–504PubMedCrossRef Verster JC, Veldhuijzen DS, Volkerts ER. Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. Clin J Pain 2006; 22(5): 499–504PubMedCrossRef
100.
Zurück zum Zitat Kr: uger HP, Kazenwadel J, Vollrath M. Grand rapids effects revisited: accidents, alcohol and risk. International Conference on Alcohol, Drugs and Traffic Safety (T’95); 1995 Aug 13–18; Adelaide Kr: uger HP, Kazenwadel J, Vollrath M. Grand rapids effects revisited: accidents, alcohol and risk. International Conference on Alcohol, Drugs and Traffic Safety (T’95); 1995 Aug 13–18; Adelaide
101.
Zurück zum Zitat Kloeden CN, McLean AJ, Moore VM, et al. Travelling speed and the risk of crash involvement. Adelaide: NHMRC Road Accident Research Unit, University of Adelaide, 1997 Kloeden CN, McLean AJ, Moore VM, et al. Travelling speed and the risk of crash involvement. Adelaide: NHMRC Road Accident Research Unit, University of Adelaide, 1997
102.
Zurück zum Zitat Ball KK, Roenker DL, Wadley VG, et al. Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc 2006; 54(1): 77–84PubMedCrossRef Ball KK, Roenker DL, Wadley VG, et al. Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc 2006; 54(1): 77–84PubMedCrossRef
Metadaten
Titel
Effects of Benzodiazepines, Antidepressants and Opioids on Driving
A Systematic Review and Meta-Analysis of Epidemiological and Experimental Evidence
verfasst von
Dr Tharaka Dassanayake
Patricia Michie
Gregory Carter
Alison Jones
Publikationsdatum
01.02.2011
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 2/2011
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/11539050-000000000-00000

Weitere Artikel der Ausgabe 2/2011

Drug Safety 2/2011 Zur Ausgabe

Correspondence

The Authors’ Reply